Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors while in the central nervous procedure, conolidine modulates alternate molecular targets. A Science Advances analyze observed that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://barbaray108wyz9.wikihearsay.com/user